• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

The Market Has Started 'Resistance' Training

All rallies begin with short-covering, but at some point, it takes real buying to keep pushing them up. Let's look at a few case studies, err, chart studies, to see if we can lift past those heavy prices.
By HELENE MEISLER
Aug 02, 2022 | 06:00 AM EDT
Stocks quotes in this article: XBI, MSOS, WMT

It was a dull day and we're getting a small pullback. That's pretty much the sum of the trading day on Monday. But I want to discuss the chart of SPDR S&P Biotech fund (XBI) , an exchange-traded fund for the biotech stocks.

Back in May, XBI, which had been a disaster for nearly 18 months, made a low. Then when it came down again in mid-June and for the first time in 2022, it did not make a lower low (which the major indexes did).

Then it lifted off in that late June rally. It gave hardly anything back when we pulled back again into July 4 (blue line). It then had a terrific surge right into the holiday.

But in July, when tech and growth stocks found their footing and rallied, the first group down in 2021 and the first group to hold in May and June, sat it out. In fact, if it wasn't for that surge during the first few days of July, biotechs might have been flat or down on the month.

Why does this matter? Why am I fussing so much? Because in early July, folks glommed onto biotech. Everyone praised the group. And now they have disappointed. Now they are on the verge of breaking down, giving back all those July gains.

Another highly speculative group, the cannabis stocks, as represented by the AdvisorShares Pure U.S. Cannabis ETF (MSOS) , made a low in early July and enjoyed a 30% rally. But those stocks stopped going up two weeks ago and are now heading down.

Why am I picking on these two groups, when I could be focused on software or semiconductors? Because as I noted here two weeks ago, all rallies begin with short-covering, but at some point, it takes real buying to keep pushing them up.

Here are two speculative groups that had terrific runs. Was it short-covering? Who knows? What we do know is that two weeks ago, the pot stocks, and a month ago, the biotechs, stopped going up. There are two parts to base building. There is the lower part, where stocks stop going down and buyers keep stepping in at a price. Then, there is the upper zone, where we wait to see if buyers are willing to push the stocks over the resistance.

With that in mind, let's revisit Walmart (WMT) , which we looked at last week when it announced, before earnings, that numbers wouldn't be ideal. The stock held -- and held well. I had said $117-$120 was the level it needed to hold and it didn't even break $120. It has since climbed all the way back. Unless it breaks up and over that $137-$138 area, it's still just working on a base.

It is quite impressive that it held and buyers stepped up to the plate near the lows. That's bullish. But will buyers be willing to push it back over the prior highs or will this turn out to be like the biotechs, where the buyers seemed to have dried up?

That's what we should watch as the market digests its overbought reading.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
TAGS: Investing | Stocks | Technical Analysis | Biotechnology |

More from Stocks

Market Weakness, July CPI, Charting Fed Economic Data, Trading Disney

Stephen Guilfoyle
Aug 10, 2022 7:18 AM EDT

Understand that recent spending plans passed in the Senate will work to counteract measures being taken by the Fed to gain the upper hand on inflation.

This Market Could Get Bumpy, So Sit Tight

Helene Meisler
Aug 10, 2022 6:00 AM EDT

Apparently Wall Street didn't get the memo about a lazy August. Let's see why volatility could make investors sweat a little bit, look at new lows and check on weakening momentum.

This Market Calls for Short-Term Plans

James "Rev Shark" DePorre
Aug 9, 2022 4:44 PM EDT

Looming price data and expected volatility could offer opportunities for very short-term traders, but building longer-term positions is a tougher task.

These 3 ETFs Offer Yield-Hungry Investors Some 'Options'

Mark Abssy
Aug 9, 2022 2:00 PM EDT

As our appetite expands to 'take what we can get' investments, let's look at three funds from Global X and see how they stack up against major index funds.

The World Gets Worse as Inflation Gets Better?

Peter Tchir
Aug 9, 2022 12:50 PM EDT

Here's the shift in the narrative I expect over the coming days.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:44 PM EDT STEPHEN GUILFOYLE

    This Holding Lights Up With Strong Earnings

    Check out the latest from TheStreet's Stocks Under...
  • 09:24 AM EDT PETER TCHIR

    Jobs Report Reaction: Incredibly Strong, But Questions to Ask

    An incredibly strong July jobs report. Not only d...
  • 08:54 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The Secret to Dealing With FOMO
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login